The Zhitong Finance App learned that on October 8, the IPO review status of the Shanghai Stock Exchange Science and Technology Innovation Board of Sykesis Biotechnology Co., Ltd. (abbreviation: Cyxis) changed to “terminated”. Due to the withdrawal of the issuance and listing application by Sykesis and its sponsor, the Shanghai Stock Exchange terminated its issuance and listing review in accordance with the relevant provisions of Article 63 of the “Shanghai Stock Exchange Stock Issuance and Listing Review Rules”.
According to the prospectus, Cyxis focuses on the R&D, production and sale of implantable interventional medical devices that can be absorbed in vivo. After more than 20 years of intensive work, the company has systematically built five leading core technology platforms, including PEG functional modification, bio-based polymer material modification, synthetic medical polymer material preparation, extracellular matrix material preparation, and self-assembled peptide material design and preparation. It has become one of the few medical device companies in China that can simultaneously lay out and mature operate various absorbable medical material platforms, forming a platform-based R&D structure with “material innovation drives product innovation”. Relying on the above platform, the company has formed an absorbable innovative medical device product system covering various departments such as neurosurgery, cardiovascular surgery, general surgery, orthopedics, and oncology radiology.
The company's absorbable vascular encapsulation medical adhesive is the only domestically produced product in this segment. Since its launch, with stable product performance and good clinical usage feedback, its market recognition has continued to increase. Currently, the company occupies about 70% of the domestic vascular encapsulation medical adhesive market share in the domestic vascular sealing adhesive field, and has successfully achieved import substitution. Currently, the market penetration rate of vascular sealing adhesives in China is about 10%. With the deepening of market promotion and continuous verification of the clinical application effects of the product, this product is expected to further increase the market penetration rate and promote the development and growth of independent brands in the field of vascular encapsulation materials in China.
The company's compound microporous polysaccharide hemostatic powder has been used clinically in China for more than 10 years. The product has maintained a high level of hemostatic effect, safety, applicability, etc., and has formed a strong brand influence and clinical recognition, and has been at the forefront of the market share in the industry segment for a long time. Currently, the company's composite microporous polysaccharide hemostatic powder has a share of 27.67% in the domestic market of micronized absorbable hemostatic materials, ranking first in the industry segment and has a stable market position.
The company's surgical anti-adhesives have been used clinically for more than 15 years. The product has performed well in terms of safety, stability and ease of use, and is highly accepted in the product market. Currently, the product has a share of 20.53% in the domestic surgical anti-adhesion materials market, ranking second in the industry, and is one of the main brands in the field of surgical anti-adhesion materials.
On the financial side, in 2023, 2024 and 2025, the company achieved operating income of about 379 million yuan, 331 million yuan, and 338 million yuan; during the same period, the company achieved net profit of about 153 million yuan, 161 million yuan, and 168 million yuan, respectively.
